Board of Directors
Jan Provis is Emeritas Professor at the Australian National University where she was Associate Dean (Research) in the ANU Medical School, and led a team investigating development and aging of the macula, including studies focussed on age-related macular degeneration. Jan has a distinguished track record in visual neuroscience, authoring more than 100 scientific papers which have attracted around 5000 citations in the scientific literature. This body of work provides a broad perspective on how the macular / foveal part of the primate retina has evolved, how it develops, the molecular factors involved, the functional constraints, and why the macula is vulnerable to degeneration. Her research team at the ANU pioneered the rodent light-induced model of photo-oxidative retinal damage, which is proving to be a very useful model for investigating therapeutic approaches for the management of dry AMD. She has a track record in leadership, mentoring of early career scientists and research consultancy.
Professor Penfold is Chief Scientist and Founder of Eye Co. Editor/Author of the textbook: “Macular Degeneration”. Held senior academic positions at Sydney University and at Australian National University and is currently an adjunct professor at ANU’s John Curtin School of Medical Research. Led the scientific team at Regenera Ltd/Advanced Ocular Systems from start up, to oversubscribed IPO on the ASX, on to transactions with Alcon, QLT and others. His initial inventions including the triamcinolone ocular injection method, were licensed by Alcon in a high value transaction in 2005, and products he developed are now on global markets with regulatory approvals, including from USFDA.
Senior executive with more than 30 years’ experience as CEO, and Managing Director of an ASX listed company and of major subsidiaries of the ophthalmic companies Allergan and Advanced Medical Optics. Operated in Australia, New Zealand and in several Asian markets based in Hong Kong and Shanghai. Independent Chair, Code of Conduct Committee, Medical Technology Association of Australia. Proven skills in the pharmaceutical, medical device, FMCG and OTC sectors with demonstrated effectiveness in leadership, strategic planning, and transformational change.
Co-founder and developer of innovative medtech, biotech and financial services companies, founding eG Capital, a preeminent life sciences financial advisory firm, Micro-X (ASX: MX1), a carbon nano technology miniaturised X-Ray company, and formerly Managing Director/Executive Chairman of Memphasys (ASX: MEM), overseeing development of the lead product, Felix™.Alison’s broad experience covers all key activities of drug development and medtech product development and private and public company boards, with a focus on governance, strategy and capital raising. Prior experience includes international engineering project management at Bechtel Corp, strategy consulting with Boston Consulting Group and executive search with Egon Zehnder International. Formerly Chair of CSIRO’s Health Sector Advisory Council.
Graham brings 37 years’ experience as CFO, with 17 of those years at EMI Music, 2 years at Time Inc Publishing Australia and the last 18 years with the ICF Holdings Group in Australia. Graham has proven CFO leadership skills across diverse business streams and augmented by 17 years as Company Secretary for ICF, which covered all elements of board governance, regulatory compliance and multiple transactions around shareholders and acquisitions. He is respected by auditors and boards for leading strong teams and delivering transparent financial and governance control.